Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients

Lay Summary The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STA...

Full description

Saved in:
Bibliographic Details
Published in:Inflammatory bowel diseases 2022-06, Vol.28 (6), p.971-976
Main Authors: Massimino, Luca, Spanò, Salvatore, Lamparelli, Luigi Antonio, Fuggetta, Davide, Peyrin-Biroulet, Laurent, Sileri, Pierpaolo, Danese, Silvio, D’Alessio, Silvia, Ungaro, Federica
Format: Article
Language:English
Subjects:
Colitis, Ulcerative
Humans
Leukocytes
Life Sciences
Piperidines
Pyrimidines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lay Summary The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STAT3/STAT6 phosphorylation.
ISSN:1078-0998
1536-4844
DOI:10.1093/ibd/izab349